
==== Front
Mol Neurodegener
Mol Neurodegener
Molecular Neurodegeneration
1750-1326
BioMed Central London

718
10.1186/s13024-024-00718-8
Letter to the Editor
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases
Calliari Anna 1
Daughrity Lillian M. 1
Albagli Ellen A. 1
Castellanos Otero Paula 1
Yue Mei 1
Jansen-West Karen 1
Islam Naeyma N. 1
Caulfield Thomas 1
Rawlinson Bailey 1
DeTure Michael 12
Cook Casey 12
Graff-Radford Neill R. 3
Day Gregory S. 3
Boeve Bradley F. 4
Knopman David S. 4
Petersen Ronald C. 4
Josephs Keith A. 4
Oskarsson Björn 3
Gitler Aaron D. 5
Dickson Dennis W. 12
Gendron Tania F. 12
Prudencio Mercedes 12
Ward Michael E. wardme@nih.gov

67
Zhang Yong-Jie zhang.yongjie@mayo.edu

12
http://orcid.org/0000-0003-2959-129X
Petrucelli Leonard petrucelli.leonard@mayo.edu

12
1 https://ror.org/02qp3tb03 grid.66875.3a 0000 0004 0459 167X Department of Neuroscience, Mayo Clinic, Jacksonville, FL USA
2 https://ror.org/02qp3tb03 grid.66875.3a 0000 0004 0459 167X Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN USA
3 https://ror.org/02qp3tb03 grid.66875.3a 0000 0004 0459 167X Department of Neurology, Mayo Clinic, Jacksonville, FL USA
4 https://ror.org/02qp3tb03 grid.66875.3a 0000 0004 0459 167X Department of Neurology, Mayo Clinic, Rochester, MN USA
5 grid.168010.e 0000000419368956 Department of Genetics, Stanford University School of Medicine, Stanford, CA USA
6 grid.94365.3d 0000 0001 2297 5165 National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD USA
7 grid.94365.3d 0000 0001 2297 5165 Center for Alzheimer’s and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD USA
27 3 2024
27 3 2024
2024
19 299 2 2024
11 3 2024
© The Author(s) 2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
This letter demonstrates the potential of novel cryptic proteins resulting from TAR DNA-binding protein 43 (TDP-43) dysfunction as markers of TDP-43 pathology in neurodegenerative diseases.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13024-024-00718-8.

http://dx.doi.org/10.13039/100013013 Target ALS Target ALS Target ALS Target ALS Target ALS Prudencio Mercedes Ward Michael E. Zhang Yong-Jie Petrucelli Leonard http://dx.doi.org/10.13039/100012312 Robert Packard Center for ALS Research, Johns Hopkins University Robert Packard Center for ALS Research, Johns Hopkins University Petrucelli Leonard http://dx.doi.org/10.13039/100000049 National Institute on Aging 5P30AG0062677 U19AG063911 U19AG063911 U19AG063911 U19AG063911 U19AG063911 U19AG063911 R01AG37491 Graff-Radford Neill R. Boeve Bradley F. Knopman David S. Petersen Ronald C. Josephs Keith A. Dickson Dennis W. Petrucelli Leonard http://dx.doi.org/10.13039/100000065 National Institute of Neurological Disorders and Stroke U54NS123743 U54NS123743 U54NS123743 R35NS097273 (17,24) R35NS097263(10,10) P01NS084974 P01NS084974 P01NS084974 P01NS084974 RF1NS120992 RF1NS120992 R01NS117461 R01NS117461 R21NS127331 Josephs Keith A. Gitler Aaron D. Dickson Dennis W. Gendron Tania F. Prudencio Mercedes Zhang Yong-Jie Petrucelli Leonard issue-copyright-statement© Editorial Group and BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcTo the editor

Aberrant accumulation of the RNA binding protein TDP-43 in the cytoplasm and its depletion from the nucleus are pathological hallmarks of several neurodegenerative diseases including subsets of frontotemporal lobar degeneration (FTLD-TDP), amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD-TDP). Loss of TDP-43 from the nucleus impairs its ability to repress cryptic exon (CE) inclusion during RNA splicing [1]. Consequently, CEs are anomalously included in critical transcripts such as STMN2 and UNC13A [2–9], which can produce truncated or destabilized RNAs and lead to a loss of their function. Recently, we and others demonstrated that some transcripts with in-frame CEs produce stable CE-containing novel proteins detectable in cerebrospinal fluid (CSF) from patients with FTLD-TDP or ALS [10, 11]. One notable example is a cryptic protein derived from the gene hepatoma-derived growth factor-like protein 2 (HDGFL2-CE), a histone-binding protein expressed throughout the brain. Accordingly, CSF HDGFL2-CE could potentially serve as a sensitive biomarker of TDP-43 pathology, illuminating the contribution of pathological TDP-43 to the clinical variability in TDP-43 proteinopathies [11]. But testing whether CSF HDGFL2-CE is indicative of TDP-43 pathology is hampered by the lack of robust methods to measure pathological TDP-43 in biofluids. To determine if HDGFL2-CE abundance can be used as a readout of the presence of TDP-43 pathology, we probed whether HDGFL2-CE is preferentially expressed in affected neuroanatomical regions with TDP-43 proteinopathy in a cohort of well-characterized post-mortem tissues from FTLD-TDP and AD-TDP cases, and whether HDGFL2-CE abundance associates with pathological TDP-43 burden.

Based on the predicted structure of HDGFL2-CE protein (Fig. S1A), we had generated a previously described rabbit polyclonal HDGFL2-CE antibody (Mayo-LP) [10] that specifically detects HDGFL2-CE but not wild-type HDGFL2 (HDGFL2-WT) proteins in lysates from TDP-43-depleted human induced pluripotent stem cells (iPSC) (Fig. S1B). Using a commercial C-terminal HDGFL2-WT antibody as the capture antibody, and our Mayo-LP HDGFL2-CE antibody as the detection antibody, we then developed a Meso Scale Discovery (MSD) immunoassay that dose-dependently detected endogenous HDGFL2-CE protein in 500‒8000 ng of total protein lysate from TDP-43-depleted iPSC-derived neurons [10]. We have since further optimized the assay by biotinylating the capture antibody, using streptavidin MSD plates, and testing different diluents (Fig. S1C−E). When using MSD Diluent 35, our modified assay detected HDGFL2-CE but not HDGFL2-WT in 16 ng of total protein in lysates from HEK293T cells overexpressing these proteins (Fig. S1D). To determine whether our assay is sufficiently sensitive to detect endogenous HDGFL2-CE, we used lysates from control and TDP-43-depleted iPSCs. Compared to Diluent 35, Diluent 100 provided a better signal to noise ratio detecting endogenous HDGFL2-CE in as little as 125 ng of total protein from TDP-43-depleted iPSC lysates (Fig. S1E).

Next, we tested if our optimized assay could detect HDGFL2-CE in brain regions of FTLD-TDP (amygdala and frontal cortex) and AD-TDP (amygdala) characterized by TDP-43 pathology [7]. Compared to cognitively normal controls (controls), HDGFL2-CE was significantly increased in the amygdala of FTLD-TDP and AD-TDP cases in unadjusted analysis and when adjusting for age at death and sex (Fig. 1A, Table S1). In contrast, frontal cortex HDGFL2-CE was significantly increased only in FTLD-TDP cases when compared to controls (Fig. 1B, Table S1). When comparing AD cases without TDP-43 pathology (AD no TDP) to AD-TDP cases, HDGFL2-CE was significantly increased in the amygdala, but not the frontal cortex, in AD-TDP (Fig. 1A, Table S1) – an expected result given the paucity of TDP-43 pathology in the frontal cortex of AD-TDP cases.Fig. 1 HDGFL2-CE proteins are increased in brain regions with TDP-43 pathology in FTLD-TDP and AD-TDP, and distinguish these TDP-43 proteinopathies from non-TDP-43 controls. Immunoassay quantification of HDGFL2-CE proteins in the amygdala (A) and frontal cortex (B) of cognitively normal controls (Ctrl, n = 27, n = 26 amygdala and n = 25 frontal cortex), FTLD-TDP (n = 67), AD-TDP (n = 70) and AD no TDP (n = 27). Data are presented as mean ± s.e.m. * P < 0.05 and **** P < 0.0001, ns: not significant. (C, D) Area under the receiver operating characteristic curves (AUC) showing the discriminatory capability of HDGFL2-CE in the amygdala or frontal cortex to distinguish FTLD-TDP from Ctrl (pink), AD-TDP from Ctrl (gold), and AD-TDP from AD no TDP (black). AUC values are shown. (E–G) Scatterplots of HDGFL2-CE protein and RNA abundance with pTDP-43 abundance in the amygdala (E) and frontal cortex (F) of FTLD-TDP patients, as well as in the amygdala of AD-TDP patients (G). Regression coefficients (β) and P values from linear regression analysis of pTDP-43 with HDGFL2-CE protein and RNA adjusting for age and sex are shown

The presence of HDGFL2-CE differentiated individuals with and without TDP-43 pathology in the amygdala: HDGFL2-CE distinguished between controls and individuals with TDP-43 pathology with an area under the receiver operating characteristic curve (AUC) of 0.85 and 0.92 for AD-TDP and FTLD-TDP, respectively, indicating good to excellent discriminatory ability (Fig. 1C). When assessing whether amygdala HDGFL2-CE protein distinguishes AD no TDP from AD-TDP, we found moderate discriminatory ability (AUC of 0.68, Fig. 1C). In the frontal cortex, HDGFL2-CE differentiated controls and FTLD-TDP with an AUC of 0.82, indicating good discriminatory ability (Fig. 1D).

Finally, phosphorylated TDP-43 (pTDP-43) burden in the amygdala and frontal cortex significantly associated with HDGFL2-CE protein and HDGFL2-CE RNA abundance in FTLD-TDP in both unadjusted analysis and in analysis adjusting for age at death, sex, and RNA integrity number (RIN), the latter for analysis of HDGFL2-CE RNA only (Fig. 1E, F, Table S2). In the amygdala of AD-TDP cases, pTDP-43 burden also associated with HDGFL2-CE protein and RNA in unadjusted and adjusted analyses (Fig. 1G, Table S2). However, estimated β coefficients where higher for HDGFL2-CE protein than HDGFL2-CE RNA indicating that HDGFL2-CE protein serves as a more accurate indicator of TDP-43 dysfunction.

Retention of CEs in mRNAs owing to TDP-43 dysfunction is well-documented in FTLD-TDP, ALS and AD-TDP [2–8], but the identification that certain in-frame CEs generate stable cryptic proteins is new [8, 10, 11]. Here, we explored the recently identified HDGFL2-CE protein. By developing a sensitive and specific immunoassay to detect HDGFL2-CE proteins, we observed that HDGFL2-CE is significantly increased in brain regions with TDP-43 pathology in FTLD-TDP and AD-TDP, associates with pTDP-43 burden, and can distinguish individuals with TDP-43 pathology from those without. In line with our findings, Irwin et al. used their HDGFL2-CE antibody to perform immunofluorescent staining of motor cortex and hippocampus tissues from patients with ALS-FTD demonstrating that HDGFL2-CE proteins accumulate in cells exhibiting pTDP-43 pathology [11]. They additionally found that, compared to controls, CSF HDGFL2-CE was statistically significantly higher in individuals likely to have TDP-43 pathology, namely presymptomatic or symptomatic C9orf72 repeat expansion carriers and patients with sporadic ALS [11].

Collectively, these findings show that the presence of HDGFL2-CE in the brain is a sensitive reporter of TDP-43 pathology in neurodegenerative diseases. These findings empower CSF HDGFL2-CE as a surrogate marker of TDP-43 pathology and dysfunction, which in turn would inform the selection of ideal participants for clinical trials of potential TDP-43-based therapeutics, and potentially enable precision medicine strategies for pathological subtypes of FTLD and AD.

Supplementary Information

Supplementary Material 1.

Acknowledgements

We thank the patients and their families for their contributions to this study.

Authors’ contributions

L.P., Y.-J.Z., M.E.W., M.P., and T.F.G. conceptualized and designed the study. A.C., L.M.D., P.C.O, M.Y., K.J.W. and M.P. carried-out the investigation. N.N.I. and T.C. generated 3D structure of cryptic HDGFL2 proteins. B.R., M.D., C.C., N.R.G., B.F.B., D.S.K., R.C.P., K.A.J., B.O., A.D.G., D.W.D., M.P., M.E.W., Y.-J.Z. and L.P. provided resources. A.C., T.F.G., M.P., M.E.W., Y.-J.Z. and L.P performed the data analysis. E.A.A., A.C., A.D.G, T.F.G, M.P., M.E.W., Y.-J.Z. and L.P. wrote the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the Target ALS Foundation (M.P., M.E.W., Y.-J.Z. and L.P.,), Robert Packard Center for ALS Research at Johns Hopkins (L.P.), the National Institutes of Health/National Institute on Aging [(5P30AG0062677: L.P.), (ALLFTD U19AG063911: N.R.G., B.F.B., D.S.K., R.C.P. D.W.D. and L.P.), (R01AG037491: K.A.J.)], the National Institutes of Health/National Institute of Neurological Disorders and Stroke [(U54NS123743: A.D.G., M.P. and L.P.); (R35NS097273: L.P.); (R35NS097263: A.D.G.); (P01NS084974: D.W.D., T.F.G., L.P. and Y.-J.Z); (RF1NS120992: K.A.J and M.P.); (R01NS117461: T.F.G. and Y.-J.Z.); and (R21NS127331: Y.-J.Z.)].

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files, or available from the corresponding authors upon reasonable request.

Declarations

Ethics approval and consent to participate

Human postmortem brain tissues from amygdala and frontal cortex were provided by the Mayo Clinic Florida Brain Bank. Diagnosis was independently ascertained by trained neurologists and neuropathologists upon neurological and pathological examinations, respectively. All participants, or the next of kin, provided written informed consent, and all protocols were reviewed and approved by the Mayo Clinic Institutional Review Board and Ethics Committee.

Consent for publication

All authors have reviewed the final manuscript and consent to publication.

Competing interests

B.F.B. receives institutional research grant support from Alector, Biogen, Transposon, Cognition Therapeutics, and GE Healthcare. B.F.B. receives an honorarium for SAB activities for the Tau Consortium. L.P. is a consultant for Expansion Therapeutics. D.S.K. serves on a Data Safety Monitoring Board for the Dominantly Inherited Alzheimer Network Treatment Unit study. D.S.K. served on a Data Safety monitoring Board for a tau therapeutic for Biogen (until 2021) but received no personal compensation. D.S.K. is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California. D.S.K. has served as a consultant for Roche, Samus Therapeutics, Magellan Health, Biovie and Alzeca Biosciences but receives no personal compensation. D.S.K. attended an Eisai advisory board meeting for lecanemab. A.D.G. is a scientific founder of Maze Therapeutics.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Anna Calliari and Lillian M. Daughrity contributed equally to this work.
==== Refs
References

1. Ling JP Pletnikova O Troncoso JC Wong PC TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD Science 2015 349 650 655 10.1126/science.aab0983 26250685
2. Brown AL Wilkins OG Keuss MJ Hill SE Zanovello M Lee WC Bampton A Lee FCY Masino L Qi YA TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A Nature 2022 603 131 137 10.1038/s41586-022-04436-3 35197628
3. Ma XR Prudencio M Koike Y Vatsavayai SC Kim G Harbinski F Briner A Rodriguez CM Guo C Akiyama T TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A Nature 2022 603 124 130 10.1038/s41586-022-04424-7 35197626
4. Melamed Z Lopez-Erauskin J Baughn MW Zhang O Drenner K Sun Y Freyermuth F McMahon MA Beccari MS Artates JW Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration Nat Neurosci 2019 22 180 190 10.1038/s41593-018-0293-z 30643298
5. Klim JR Williams LA Limone F Guerra San Juan I Davis-Dusenbery BN Mordes DA Burberry A Steinbaugh MJ Gamage KK Kirchner R ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair Nat Neurosci 2019 22 167 179 10.1038/s41593-018-0300-4 30643292
6. Prudencio M Humphrey J Pickles S Brown AL Hill SE Kachergus JM Shi J Heckman MG Spiegel MR Cook C Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia J Clin Invest 2020 130 6080 6092 10.1172/JCI139741 32790644
7. Estades Ayuso V Pickles S Todd T Yue M Jansen-West K Song Y Gonzalez Bejarano J Rawlinson B DeTure M Graff-Radford NR TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains Mol Neurodegener 2023 18 57 10.1186/s13024-023-00646-z 37605276
8. Chang K Ling JP Redding-Ochoa J An Y Li L Dean SA Blanchard TG Pylyukh T Barrett A Irwin KE Loss of TDP-43 splicing repression occurs early in the aging population and is associated with Alzheimer’s disease neuropathologic changes and cognitive decline Acta Neuropathol 2023 147 4 10.1007/s00401-023-02653-2 38133681
9. Chung M Carter EK Veire AM Dammer EB Chang J Duong DM Raj N Bassell GJ Glass JD Gendron TF Cryptic exon inclusion is a molecular signature of LATE-NC in aging brains Acta Neuropathol 2024 147 29 10.1007/s00401-023-02671-0 38308693
10. Seddighi S Qi YA Brown AL Wilkins OG Bereda C Belair C Zhang YJ Prudencio M Keuss MJ Khandeshi A Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD Sci Transl Med 2024 16 eadg7162 10.1126/scitranslmed.adg7162 38277467
11. Irwin KE Jasin P Braunstein KE Sinha IR Garret MA Bowden KD Chang K Troncoso JC Moghekar A Oh ES A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD Nat Med 2024 30 382 10.1038/s41591-023-02788-5 38278991
12. Jumper J Evans R Pritzel A Green T Figurnov M Ronneberger O Tunyasuvunakool K Bates R Zidek A Potapenko A Highly accurate protein structure prediction with AlphaFold Nature 2021 596 583 589 10.1038/s41586-021-03819-2 34265844
13. Goddard TD Huang CC Meng EC Pettersen EF Couch GS Morris JH Ferrin TE UCSF ChimeraX: Meeting modern challenges in visualization and analysis Protein Sci 2018 27 14 25 10.1002/pro.3235 28710774
14. Coban MA Morrison J Maharjan S Hernandez Medina DH Li W Zhang YS Freeman WD Radisky ES Le Roch KG Weisend CM Attacking COVID-19 progression using multi-drug therapy for synergetic target engagement Biomolecules 2021 11 787 10.3390/biom11060787 34071060
